Saturday, October 8, 2011
In the United Kingdom, the Cancer Research UK has begun a pilot program for mass genetic screenings of cancer tumors. They plan to take the excess component of biopsies and make a library of genes and mutations in the tumors in the hopes of gaining and understanding of which treatments will be effective on what cancer types. The benefit of a centralized system is that it allows for many researchers to have access to samples but also maintains standards of patient privacy. There also exists the hope that this will provide a model for bringing further personalized medicine into the British healthcare system.